Everpar Advisors LLC Buys 930 Shares of Johnson & Johnson (NYSE:JNJ)

Everpar Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,224 shares of the company’s stock after buying an additional 930 shares during the period. Johnson & Johnson makes up about 0.9% of Everpar Advisors LLC’s investment portfolio, making the stock its 20th largest holding. Everpar Advisors LLC’s holdings in Johnson & Johnson were worth $1,696,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in JNJ. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on JNJ shares. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Wall Street Zen downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 22nd. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Trading Up 0.2%

Shares of NYSE:JNJ opened at $156.90 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a market cap of $377.52 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The stock has a 50 day moving average of $153.84 and a 200 day moving average of $153.71.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.